The pyruvate mimetic, DCA, redirects the tumour metabolism from glycolytic pathway to OXPHOS, inducing a decreasing the mitochondrial membrane potential and activating the K+ channel Kv1.5.11, 39 DCA is normally used to treat human hereditary mitochondrial metabolic diseases and lactic acidosis, but it has been recently evaluated in several pre‐clinical cancer therapies including prostate,40 colon 41 and breast cancer.42 DCA safety and efficacy has been studied in glioblastoma patients in a clinical trial (NCT01111097), but no results are published until now. This evidence concerns the gene KCNA5 and breast cancer.